889126-33-4 Usage
General Description
Methyl 1-(2-chloropyrimidin-4-yl)piperidine-4-carboxylate is a chemical compound with an exact mass of 231.056396 in its mono-isotopic form. It belongs to the category of organohalogens and is likely to be used in various industries such as pharmaceuticals and agrochemicals. The chemical structure features a chloropyrimidine ring attached to a piperidine ring with a carboxylate functional group. Detailed properties such as its boiling point, melting point, optical rotatory power, etc. may vary based on factors like pressure and temperature, and information about these properties might be available in specialized scientific resources. Always ensure handling such chemicals under guided supervision as their toxicity level or hazard information is usually detailed out in MSDS (Material Safety Data Sheet).
Check Digit Verification of cas no
The CAS Registry Mumber 889126-33-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,9,1,2 and 6 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 889126-33:
(8*8)+(7*8)+(6*9)+(5*1)+(4*2)+(3*6)+(2*3)+(1*3)=214
214 % 10 = 4
So 889126-33-4 is a valid CAS Registry Number.
InChI:InChI=1/C11H14ClN3O2/c1-17-10(16)8-3-6-15(7-4-8)9-2-5-13-11(12)14-9/h2,5,8H,3-4,6-7H2,1H3
889126-33-4Relevant articles and documents
FUSED TRIAZOLE TACHYKININ RECEPTOR ANTAGONISTS
-
Page/Page column 29-30, (2008/06/13)
The present invention is directed to certain fused triazole compounds which are useful as neurokinin-1 (NK-I) receptor antagonists, and inhibitors of tachykinin and in particular substance P- The invention is also concerned with pharmaceutical formulation
CYCLOALKYL PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS
-
Page/Page column 22-23, (2010/11/08)
The present invention is directed to certain piperidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations co
